lated by Robison and Morgan⁹ from the products of

yeast fermentation. The enzyme has been only partially purified and still contains the enzymes which transform glucose-6-phosphate into glucose-1-phosphate and into fructose-6-phosphate, but the most simple explanation of the chemical changes observed is the equation

UDPG + glucose-6-phosphate	e —>			
	UDP +	trehalose phosphate		
(9) R. Robison and W. T. J. Morgan, Biochem. J., 22, 1277 (1928).				
INSTITUTO DE INVESTIGACIONE				
BIOQUÍMICAS, FUNDACIÓN CAM	IPOMAR	L. F. Leloir		
Julián Alvarez 1719		E. Cabib		

Julián Alvarez 1719 Buenos Aires, Argentina

RECEIVED SEPTEMBER 14, 1953

PATHWAYS OF GLUCOSE CATABOLISM¹

The catabolism of glucose via the Embden-Meyerhof glycolytic pathway would be anticipated to result in the simultaneous contributions to carbon dioxide of carbon atoms 1 and 6 of glucose. By an alternative oxidative pathway via 6-phosphogluconate,² known to occur in various biological systems, the appearance of C-1 as carbon dioxide would precede that of C-6.

Glucose-1-C¹⁴ and glucose-6-C¹⁴, the latter kindly supplied by Dr. John C. Sowden, have been compared as precursors of C¹⁴O₂ when incubated with rat diaphragm sections, kidney slices and liver slices. The experimental conditions were identical with those described.⁸ No significant differences in radiochemical yields of C¹⁴O₂ between the two substrates was noted with diaphragm slices. The ratio

$\frac{\text{Yield of } C^{14}O_2 \text{ from glucose-}6-C^{14}}{\text{Yield of } C^{14}O_2 \text{ from glucose-}1-C^{14}}$

is close to unity. With kidney slices, the value of this ratio is approximately 0.9. With liver slices the mean value of this ratio is 0.36.

From studies⁸ in which glucose-1-C¹⁴, uniformly labeled glucose-C¹⁴, lactate-1-C¹⁴, lactate-2-C¹⁴ and lactate-3-C¹⁴ were compared as precursors of C¹⁴O₂, no evidence was found supporting the occurrence of a non-glycolytic pathway in rat diaphragm sections. With kidney slices the data suggested the presence of an active non-glycolytic pathway, whereas with liver slices it appeared that the bulk of the carbon dioxide derived from glucose arose by a non-glycolytic route. A quantity, $E_{\rm max}$, was defined as the maximal contribution of the glycolytic pathway to the over-all conversion of glucose to carbon dioxide. This was calculated to be 0.91, 0.72 and 0.23 for diaphragm, kidney and liver, respectively. These quantities are to be compared with the ratios obtained in the present experiments, and satisfactory agreement is to be noted.

The present experimental approach to the ques-

(1) This work was carried out while Dr. Ben Bloom held a Postdoctoral Fellowship from the Atomic Energy Commission.

(2) B. L. Horecker, in W. D. McElroy and B. Glass, "Phosphorus Metabolism," The Johns Hopkins Press, Baltimore, Md., Vol. I, (1951) p. 117.

(3) B. Bloom, M. R. Stetten and D. Stetten, Jr., J. Biol. Chem., **204**, 681 (1953).

TABLE I

IN VITRO CONVERSION OF GLUCOSE-C¹⁴ TO C¹⁴O₄ Tissues were incubated for 3 hours at 37.8° with 5.5 ml. of bicarbonate buffer containing 50 μ M. each of glucose, gluconate, lactate and acetate. The location of the isotope in the labeled glucose is indicated below. Radiochemical yields of C¹⁴O₂ are calculated per 500 mg. of tissue.

Tissue	Radiochemi CO: from g -1-C ¹⁴		Ratio G-6-C ¹⁴ G-1-C ¹⁴
Diaphragm sections	3.76 3.79 3.63 3.89	4.41 3.54 3.90 3.56	$1.17 \\ 0.93 \\ 1.07 \\ 0.92$
Kidney slices	$5.46 \\ 5.38 \\ 5.04$	$5.03 \\ 5.02 \\ 4.38$	$0.92 \\ 0.93 \\ 0.87$
Liver slices	7.64 7.19 6.76 10.4 8.49	2.62 2.46 2.14 3.76 3.57	$\begin{array}{c} 0.34 \\ 0.34 \\ 0.32 \\ 0.36 \\ 0.42 \end{array}$

tion of the estimation of various pathways of glucose catabolism is simpler than that previously employed and its interpretation requires fewer assumptions.

DIVISION OF NUTRITION AND PHYSIOLOGY THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK, INC. BEN BLOOM NEW YORK, N. Y. DEWITT STETTEN, JR. RECEIVED SEPTEMBER 21, 1953

ALKALOID STUDIES. II.¹ ISOLATION OF RESERPINE AND NARCOTINE FROM RAUWOLFIA HETEROPHYLLA ROEM. AND SCHULT.

Sir:

Extracts of the Indian plant Rauwolfia serpentina Benth., characterized by an abundance of alkaloids,² have been used for some time in India for the treatment of hypertension and other clinical conditions.³ Acute interest was created by the recent report⁴ of the isolation from *R. serpentina* of a crystalline alkaloid, named reserpine, possessing pronounced sedative and hypotensive properties.⁶ Several *R. serpentina* extracts of varying degrees of purity are already being employed clinically in this country.

At least one Rauwolfia species—R. heterophylla Roem. and Schult.—is indigenous to Central and South America and in connection with our present investigations of natural products from Latin American sources it appeared of interest to examine this plant. Such a study seemed especially pertinent because of the report⁶ that the Guatemalan R. heterophylla ("chalchupa") contains two amorphous alkaloids—chalchupine A and B (m.p. (?) ca. 170 and 240°, respectively)—to which were assigned the rather implausible formulas C₁₄-H₂₁N₃O₁₂ and C₁₆H₂₄N₆O₁₁. The presence of the

(1) Paper I, C. Djerassi, N. Frick and L. E. Geller, THIS JOURNAL, **75**, 3632 (1953).

(2) Cf. A. Stoll and A. Hofmann, Helv. Chim. Acta, 36, 1143 (1953), and references cited therein.

(3) Inter al., M. D. Chakravarti, Brit. Med. J., 1390 (1953).

(4) J. M. Müller, E. Schlittler and H. J. Bein, *Experientia*, **8**, 338 (1952). No empirical formula for reservine was established.

(5) H. J. Bein, ibid., 9, 107 (1953).

(6) E. C. Deger, Arch. Pharm., 275, 496 (1937).

Sir: